Up­dat­ed: Lil­ly re­ports mid-stage win for tirzepatide in fat­ty liv­er dis­ease MASH

Eli Lil­ly an­nounced Tues­day that its di­a­betes and weight loss drug tirzepatide suc­ceed­ed in a Phase II study for MASH, or meta­bol­ic dys­func­tion-as­so­ci­at­ed steato­hep­ati­tis. …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER